04 March 2008
Gilde Healthcare Investment in Acacia Pharma
Cambridge, UK – 4th March 2008: Acacia Pharma Ltd. (Acacia) announces the completion of an investment by Gilde Healthcare Partners. The investment will be used to execute its business plan, by advancing the company’s product portfolio.
Acacia is a hospital based pharmaceutical company with a therapeutic focus in cancer supportive care and peri-operative care. The company’s objective is to build a sustainable pharmaceutical business, creating value internally and selling its products in Europe.
Dr Steven Powell (CEO, Plethora Solutions) and Pieter van der Meer (Senior Partner, Gilde Healthcare Partners) have joined the Board of Acacia, Dr Powell as Chairman.
Dr Julian Gilbert, CEO of Acacia commented, “Acacia Pharma is delighted to have concluded this investment by Gilde Healthcare. The company has a clear vision which Gilde has endorsed. These funds allow us to validate and grow our portfolio, realising product opportunities of real value, and to build a sustainable business for stakeholders.”
Pieter van der Meer of Gilde Healthcare Partner added, “The management team at Acacia has a track record of building teams and start-up organisations, and of successfully identifying and commercialising valuable, innovative, lower risk, pharmaceutical products. In addition, the areas of therapeutic focus adopted by the company are within areas of high unmet need. Gilde is therefore very pleased to support the company and looks forward to working with management to achieve success.”